Martin Delaney Collaboratories for HIV Cure Research

The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), has released a forecasted grant opportunity titled "Martin Delaney Collaboratories for HIV Cure Research" under opportunity number FOR-AI-27-001. This grant continues NIAID’s mission to advance HIV cure research through its Martin Delaney Collaboratories (MDCs) program, which focuses on developing therapeutic strategies to control or eradicate HIV without lifelong antiretroviral therapy. Special emphasis is placed on addressing the unique needs of children living with HIV. This program seeks to accelerate progress toward an HIV cure by supporting collaboration among academic researchers, governmental scientists, private sector entities, and community stakeholders. By fostering these strategic partnerships, the MDCs aim to facilitate basic, translational, and clinical research efforts. The program also intends to leverage shared research resources and technologies to increase efficiency and reduce duplication, offering economies of scale for the projects involved. The funding instrument type for this opportunity is a cooperative agreement, with a discretionary funding category focused on health-related activities. An estimated total of $20,000,000 in program funding is anticipated, and approximately six awards are expected to be made. No cost sharing or matching funds are required to apply. Awards will be made under Assistance Listing Number 93.855 – Allergy and Infectious Diseases Research. Eligible applicants include a wide range of organizations such as county governments, 501(c)(3) nonprofits (excluding institutions of higher education), public and private institutions of higher education, independent school districts, public housing authorities, federally recognized Native American tribal governments, non-federally recognized tribal organizations, for-profit organizations (excluding small businesses), small businesses, and state governments. This broad eligibility ensures diverse institutional participation in the program. The estimated posting date for the funding announcement is April 21, 2026, with an anticipated application due date of August 19, 2026. Awards are projected to be announced on March 1, 2027, which is also the expected start date for funded projects. This grant is part of the fiscal year 2027 funding cycle and does not operate on a rolling basis. The announcement is currently in a forecast stage and not yet open for applications. For additional details, interested applicants can contact Diane Lawrence, Ph.D., at the National Institute of Allergy and Infectious Diseases. She can be reached via email at diane.lawrence2@nih.gov or by phone at 240-627-3202. Further information will be provided upon official release of the funding opportunity.